Las Condes

76 / 144

356
66. Mattsson N, Carrillo MC, Dean RA, Devous MD, Nikolcheva T,
Pesini P et al (2015). Revolutionizing Alzheimer’s disease and
clinical trials through biomarkers. Alzheimer’s & Dementia:
Diagnosis, Assessment & Disease Monitoring; 1: 412-419.
67. Heurling K, Leuzy A, Zimmer ER, Lubberink M, Nordberg
A (2016). Imaging β-amyloid using [18F]flutemetamol
positron emission tomography: from dosimetry to clinical
diagnosis. Eur J Nucl Med Mol Imaging; 43: 362–373.
68. Okamura N, Furumoto S, Fodero-Tavoletti MT, Mulligan RS,
Harada R, Yates P et al (2014). Non-invasive assessment
of Alzheimer’s disease neurofibrillary pathology using
18F-THK5105 PET. Brain: 137; 1762–1771.
69. Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW.
(1991). The topographical and neuroanatomical distribution
of neurofibrillary tangles and neuritic plaques in the cerebral
cortex of patients with Alzheimer’s disease. Cereb Cortex;
1: 103–16.
70. Guidotti C, Farioli D, Gaeta MC, Giovannini E, Lazzeri P,
Meniconi M, Ciarmiello A. (2013). SPECT radiopharmaceuticals
for dementia. Curr Radiopharm; 6(4): 192-207.
71. Pimlott SL, Ebmeier KP. (2007). SPECT imaging in dementia.
Br J Radiol 80 Spec No 2: S153–S159
72. Valotassiou V, Sifakis N, Papatriantafyllou J, Angelidis G,
Georgoulias P. The Clinical Use of SPECT and PET Molecular
Imaging in Alzheimer’s Disease (2011). En de la Monte S
(ed). The Clinical Spectrum of Alzheimer’s Disease - The
Charge Toward Comprehensive Diagnostic and Therapeutic
Strategies, InTech, Croacia.
73. O’Brien JT. (2007). Role of imaging techniques in the diagnosis
of dementia. The British Journal of Radiology, 80 (2007),
S71–S77
74. Nobili F, De Carli F, Frisoni GB, Portet F, Verhey F, Rodriguez
G, et al. (2009). SPECT predictors of cognitive decline and
Alzheimer’s disease in mild cognitive impairment. J Alzheimers
Dis; 17(4): 761-72.
75. Yeo JM, Lim X, Khan Z, Pal S. (2013). Systematic review of the
diagnostic utility of SPECT imaging in dementia. Eur Arch
Psychiatry Clin Neurosci; 263: 539-552
76. Díaz F, Mena I, Gómez G (2002). Diagnóstico precoz de
enfermedad de Parkinson: Neurospect del transportador de
Dopamina. Rev Chil Neuro-Psiquiat; 40: 243-52
77. Scherfler C, Schwarz J, Antonini A, Grosset D, Valldeoriola F,
Marek K, et al. (2007) Role of DAT-SPECT in the diagnostic
work up of parkinsonism. Mov Disord; 22(9): 1229-38.
78. Rojas GM, Fuentes J, Gálvez M, Margulies DS. (2015).
Augmented Reality rsfc-MRI Visualization Aplication:
ARiBraiN3T, iBraiN, iBraiNEEG: New Versions, 21th Annual
Meeting of the Organization for Human Brain Mapping,
Honolulu, Hawaii, USA.
79. Díaz F, Mena I, Gómez G (2001). NeuroSPECT en el diagnóstico
precoz de enfermedad de Parkinson: 99mTc-Trodat-1
demuestra distribución del transportador de dopamina (DAT).
Alasbimn Journal, ISSN: 0717 - 4055.
[REV. MED. CLIN. CONDES - 2016; 27(3) 338-356]